stockrow
Friday 6 November 2026
Export IRTC’s income statement to Excel — free account
iRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
90.26
39.93
−30.67%
Follow IRTC
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.41 | 4.74 | 4.87 | 7.60 | |
P/FCF ratio |
509.69 | 100.39 | 204.58 | 164.50 | |
P/Operating CF |
847.69 | 76.60 | (146.58) | 216.65 | |
P/B ratio |
21.24 | 21.04 | 23.80 | 37.18 | |
Price to Tangible BV |
21.35 | 21.14 | 23.93 | 37.39 | |
EV/Sales |
4.53 | 4.83 | 5.01 | 7.70 | |
EV/EBITDA |
2,576.56 | 2,656.23 | 0.00 | 0.00 | |
EV/Operating CF |
69.57 | 46.33 | 63.10 | 71.18 | |
EV/FCF |
523.62 | 102.22 | 210.57 | 166.74 | |
Quick Ratio |
3.14 | 3.45 | 4.79 | 4.34 | |
Current Ratio |
3.57 | 3.86 | 5.17 | 4.63 | |
Net Debt/EBITDA |
0.00 | 14.20 | (10.53) | 9.91 | |
Debt/Assets |
59.72% | 59.55% | 64.62% | 63.67% | |
Debt/Equity |
3.68 | 3.50 | 4.03 | 4.25 | |
Asset Turnover |
0.82 | 0.80 | 0.82 | 0.77 | |
Operating CF/Net income |
(0.15) | (134.07) | 1.88 | 4.70 | |
Capex/Depreciation |
0.00 | (2.01) | (1.04) | (2.69) | |
Interest Coverage |
(9.87) | (0.77) | (4.92) | 0.69 | |
Research and Development Expense of Revenue |
9.43% | 8.99% | 10.86% | 10.43% | |
Selling, General and Administrative Expense of Revenue |
56.70% | 58.73% | 68.15% | 58.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.80% | 8.94% | 10.78% | 10.10% | |
Graham Net Nets |
(0.05) | (0.04) | (0.04) | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.03%) | (0.36%) | (0.73%) | (0.79%) | |
Free Cash Flow Yield |
0.20% | 1.00% | 0.49% | 0.61% | |
Revenue per Share |
6.69 | 6.81 | 6.13 | 6.53 | |
Operating CF per Share |
0.13 | 1.55 | (0.81) | 0.82 | |
Capex per Share |
(0.48) | (0.41) | (0.21) | (0.37) | |
Free Cash Flow per Share |
(0.35) | 1.14 | (1.02) | 0.45 | |
Cash per Share |
16.94 | 17.97 | 16.91 | 18.24 | |
Shareholders Equity per Share |
5.35 | 5.65 | 4.96 | 4.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.35 | 5.65 | 4.96 | 4.77 | |
Free Cash Flow |
(11.54) | 37.52 | (33.08) | 14.49 | |
Working Capital |
525.48 | 559.86 | 548.81 | 550.88 | |
Capital Expenditures |
(15.98) | (13.56) | (6.90) | (11.72) | |
Net Current Asset Value |
(184.12) | (151.49) | (164.60) | (164.53) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.06 | 0.03 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
78.64 | 83.21 | 80.75 | 77.82 | |
Average Payables |
11.84 | 15.09 | 10.25 | 4.74 | |
Average Inventory |
21.39 | 20.46 | 19.07 | 17.84 | |
Average Assets |
1,043.33 | 1,028.73 | 966.23 | 975.75 | |
Average Common Equity |
149.50 | 144.82 | 123.94 | 121.83 |
Columns are period end dates · fundamentals updated 5 Nov 2026